ChatRWD™ from Atropos Health Exceeds Expectations in Beta and now Available to Clinicians and Researchers seeking Personalized Evidence

Overwhelmingly Positive Performance and Results from Beta Users Accelerate Product Availability to Additional Users

PALO ALTO, Calif.--(BUSINESS WIRE)--Atropos Health, the pioneer in translating real-world clinical data into high-quality personalized real-world evidence for care, today announced the release of ChatRWD, after a successful beta program. The company previously published ChatRWD’s superior performance over other large language models (LLMs) when it comes to trust, quality, and accuracy (limited hallucinations).

ChatRWD™ reduces the time to produce high-quality, publication-grade real-world evidence from months to minutes through a chat-based AI co-pilot. During the beta program, over 2,000 questions were asked by testers from dozens of health system and life science organizations. Testers reported significant time savings over other forms of “information foraging” such as literature reviews and second opinion consults, which can take hours and days. The average time from question to study was 5.23 minutes.

ChatRWD provides a unique vertical user experience and questions are answered with data from the Atropos Evidence™ Network, the largest federated data network with over 300 million patient records. Every answer comes with a Real World Fitness Score™ (RWFS) - evaluating the “fit-for-purpose” of the dataset used to answer the question. The average RWFS score across the questions in the evaluation was 79.8, indicating high quality data.

During the beta, Atropos Health conducted a comparison of LLMs, which highlighted several critical outcomes: General-purpose LLMs (ChatGPT-4, Claude 3 Opus, Gemini Pro 1.5) produced relevant and evidence-based answers less than 10% of the time. ChatRWD outperformed all other LLMs, completing 94% of the answers. Independent physician reviewers found that ChatRWD produced the best answers for novel questions in 87% of the cases.

Since the beta launch, substantial technical advancements were made to ChatRWD including a 4x increase to the phenotype library, expansion to support multiple study designs including case series, cross sectional, and comparative analysis studies, the ability to detect study design, and integrating customizable general study parameters. With these advancements, Atropos Health predicts ChatRWD will be able to answer 70-80% of all potential questions across both descriptive and causal use cases and enable 10x the study volume per user.

"The pace of innovation in AI and LLM technologies and their adoption in healthcare is rapid," said Neil Sanghavi, President of Atropos Health. "High-quality clinical evidence must remain the cornerstone of value in healthcare. ChatRWD's results during the beta outperformed our expectations - both technically and on user satisfaction - which led us to today’s release."

ChatRWD is the first application incorporating chat-to-database capability and agents to help healthcare leaders advance and accelerate evidence generation rapidly, saving organizations valuable time, money, and staffing resources. Today’s release allows clinicians from health systems and life sciences organizations to set-up an account and ask two clinical questions at no charge.

Come see a live demo today at HLTHUSA 2024 on the Newsroom stage (#5046) 3:30PM PT or register to use ChatRWD at https://www.atroposhealth.com/chatrwd/

About Atropos Health

Atropos Health is the developer of GENEVA OS™, the operating system for rapid healthcare evidence across a robust network of real-world data. Healthcare and life science organizations work with Atropos Health to close evidence gaps from bench to bedside, improving individual patient outcomes with data-driven care, expediting research that advances the field of medicine, and more. We aim to transform healthcare with timely, relevant real-world evidence.

To learn more about Atropos Health, visit www.atroposhealth.com or connect through LinkedIn or follow on X (Twitter) @AtroposHealth.